Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at UBS Global Healthcare Conference
SAN DIEGO, Nov. 12, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer Kameel Farag will present company updates in a fireside chat today at 4:15 pm PT at the UBS Global Healthcare Conference in Rancho Palos Verdes, Calif., where he will detail Aspen’s latest developments and future strategic…
Aspen Neuroscience Announces Collaboration and License Agreement with Cell X Technologies
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — Aspen Neuroscience has entered into a collaboration and license agreement with Cell X Technologies to advance Aspen’s plans for automating the iPSC stage of its autologous manufacturing platform. Aspen will leverage its established bioinformatics-based platform, and will lead…
Endpoints News Honors Aspen Neuroscience Co-Founder Dr. Jeanne Loring in “20 Women Breaking New Ground”
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — EndPoints News has named Jeanne Loring, PhD, Aspen Neuroscience co-founder and senior advisor, a recipient of the 20 Women Breaking New Ground in BioPharma. The publication’s annual 2024 Women in BioPharma R&D Special Report recognizes the field’s most inspiring…
Aspen Neuroscience to Showcase Advances in Autologous Cell Therapy Development at 2024 Cell & Gene Meeting on the Mesa
SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ — Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the latest therapeutic and corporate developments, at the annual Cell & Gene Meeting on the Mesa, held this week in Phoenix, Ariz. and live-streamed globally….
Aspen Neuroscience Announces Expansion of Autologous Cell Therapy Manufacturing in San Diego
Company Outlines Plans for Industrialization of Personalized Cell Therapy Manufacturing SAN DIEGO, Oct. 1, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized (autologous) cell therapies, announced the expansion of its San Diego footprint near its headquarters in Torrey Pines, with a…
Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. About…
Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease
SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week…
Study of ANPD001 Autologous Neuronal Cell Replacement Treatment Approach Published in Journal of Neurosurgery
SAN DIEGO, July 29, 2024 /PRNewswire/ — The Journal of Neurosurgery has published online a study by the Wisconsin National Primate Research Center at the University of Wisconsin, Madison regarding a novel cell transplantation approach being used for delivery of ANPD001, an autologous, dopaminergic neuronal cell replacement under investigation…
Aspen Neuroscience to Present at 2024 Raymond James Biotech Private Company Showcase July 18
SAN DIEGO, July 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the 2024 Raymond James Biotech Private Company Showcase on Thursday,…
Aspen Neuroscience to Present at Stifel 2024 Cell Therapy Forum July 9
SAN DIEGO, July 8, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum this Tuesday, July…
Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement Neurons
Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO, June 20, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled in the recently launched…
Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting
Presentations Cover Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease SAN DIEGO and VANCOUVER, BC, May 30, 2024 /PRNewswire/ — Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the…
Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)
Award Will Support the First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, May 15, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a California-based private biotechnology company developing personalized regenerative therapies, has received a CLIN2 grant award of $8 million from the California…
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety…
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company’s executive management team in a new role as Senior Vice President, Therapeutic…
Aspen Neuroscience Appoints Ana Sousa Chief Regulatory Officer
SAN DIEGO, Jan. 16, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today the appointment of Ana Sousa, MSJ as the company’s Chief Regulatory Officer. Since 2021, Ms. Sousa has…
Aspen Neuroscience to Present at Future of Parkinson’s Disease Conference
SAN DIEGO and AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ — This week, Aspen Neuroscience will present to the Parkinson’s community at the Future of Parkinson’s Disease conference, held November 30 – December 3, in Austin. The joint annual conference is hosted by the Parkinson’s Foundation and the Parkinson…
Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
SAN DIEGO, CALIF., November 21, 2023 – Biocom California, the association representing the California life sciences industry, has announced that Andrés Bratt-Leal, PhD, Aspen Neuroscience co-founder and senior vice-president of research and development, is a recipient of the 2023 Life…
FDA Grants Fast Track Designation to ANPD001, Autologous Investigational Cell Therapy for the Treatment of Parkinson’s Disease
SAN DIEGO, Oct. 19, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the treatment of Parkinson’s disease (PD) to improve motor function. ANPD001, is a personalized (autologous) cell…
Aspen Neuroscience to Partner with Rune Labs and Emerald Innovations to Incorporate both Active and Passive Digital Health Monitoring in Trial Ready Cohort Screening Study
Screening Study to Include Multiple Objective Measures of Active and Passive Symptom Capture from Parkinson’s Disease Impact on Motor Function SAN DIEGO, Aug. 24, 2023 /PRNewswire/ — Aspen Neuroscience today announced that it is partnering with Emerald Innovations, a pioneer in the…
Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson’s Disease
Aspen Will Initiate First Multicenter Phase 1/2a Clinical Trial of an Autologous iPSC Based Therapy in the U.S. SAN DIEGO, Aug. 8, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug…
Preclinical Safety and Efficacy Data for ANPD001 Presented by Dr. Andres Bratt-Leal at 2023 World Parkinson Congress in Barcelona
SAN DIEGO, July 6, 2023 /PRNewswire/ — On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for…
Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona
SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for…
Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions
SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International…
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
SAN DIEGO Calif., December 21, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley…
CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer
SAN DIEGO, Oct. 19, 2022 – Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company’s executive team.
Dr. Xiaokui Zhang to Present Aspen Neuroscience, Inc. at 2022 Cell & Gene on the Mesa
SAN DIEGO, Oct. 11, 2022 — This week Xiaokui Zhang, Ph.D., Chief Scientific Officer of Aspen Neuroscience, Inc. will present at the 2022 Cell & Gene Meeting on the Mesa Conference in Carlsbad, Calif. including presenting a live corporate update and participating in a…
NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting
SAN DIEGO, June 22, 2022 — Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams, Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif. Dr. Williams’ podium presentation, “NeuriTest: A…
Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners
Will Fund Clinical Trials of Company’s First iPSC-derived Autologous Dopamine Neuron Replacement for Parkinson’s Disease FOR IMMEDIATE RELEASE CONTACT:Angelyn Lowemedia@aspenneuro.com SAN DIEGO, Calif., May 9, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the…
Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson’s Disease
SAN DIEGO, Calif., April 12, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies, including the first autologous neuron replacement for Parkinson’s disease (PD), announced that this month it will launch the…
Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer
SAN DIEGO, Calif., November 18, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and…
Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
SAN DIEGO, Calif., Nov. 9, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company’s executive team
Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
SAN DIEGO, July 12, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Ana Sousa has joined the company as senior vice president of regulatory…
Caryn Peterson Joins ASPEN Neuroscience Board of Directors
SAN DIEGO, June 22, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Caryn Peterson, executive vice president of Regulatory Affairs for Gossamer Bio, has…
Aspen Neuroscience announces appointment of Damien McDevitt, PhD as President and Chief Executive Officer
SAN DIEGO, January 25, 2021 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced today that it has appointed biotech leader Damien McDevitt, PhD, as President and Chief Executive Officer….
Aspen Neuroscience to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
SAN DIEGO, October 5, 2020 — Aspen Neuroscience announced today that Howard Federoff, MD, PhD, Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16, 2020. Organized by the…
Aspen Neuroscience announces management transition
SAN DIEGO, Aug. 3, 2020 /PRNewswire/ – Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced that Dr. Jeanne Loring, co-founder and Chief Scientific Officer, will transition to the role…
Aspen Neuroscience Announces Reconstitution of the Board of Directors with the Addition of Seasoned Industry Executives
SAN DIEGO, April 6, 2020 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the reconstitution of its Board of Directors, including a new Board Chair, following the closing of its Series A financing of $70 million.
Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease
SAN DIEGO, Apr. 1, 2020 /PRNewswire/ — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.
Aspen Neuroscience announces board of directors and scientific advisory board
SAN DIEGO, Jan. 9, 2020 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, has announced the members of its Board of Directors and Scientific Advisory Board. These boards bring together many of the world’s most distinguished industry and academic minds to deliver Aspen’s personalized cell therapy to persons suffering with Parkinson disease.
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease
SAN DIEGO, Dec. 12, 2019 /PRNewswire/ — Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round — led by Domain Associates and Axon Ventures and including Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32 — to develop the first autologous cell therapies for Parkinson’s disease.
First-in-kind Human 3-dimensional Models of Parkinson’s Disease and Progressive Multiple Sclerosis Launching to the International Space Station
LOUISVILLE, December 02, 2019, 10:00 AM EST — (BUSINESS WIRE) — The National Stem Cell Foundation (NSCF) announced today that research teams from Aspen Neuroscience and the New York Stem Cell Foundation (NYSCF) Research Institute will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the nineteenth SpaceX Commercial Resupply Services (CRS-19) mission, scheduled to launch December 4th from the Kennedy Space Center in Cape Canaveral, Florida.